The claimants in most of the pharma lawsuits want to see an end to what they characterize as aggressive and misleading opioid marketing as well as help in shouldering the enormous cost to states, counties and cities now dealing with rising levels of addiction and overdose deaths.
As healthcare institutions grapple with the opioid crisis, one increasingly important focus of their efforts to improve addiction treatment is applying innovative design concepts to both new and renovated treatment facilities.
The four accrediting organizations in the behavioral health space have a complaint process for patients/clients/consumers and staff. Most offer a toll-free number that is posted prominently in the facility.
After an initial platform deal, private equity investors look for secondary, add-on deals that enhance their portfolios by filling gaps and building scale. Here are five things to know about follow-on deals.
In addition to declaring the opioid crisis a public health emergency, President Donald Trump on Thursday announced a policy to expedite the waiver process for states requesting an IMD exclusion workaround.
When the team at Footprints to Recovery took a step back to evaluate the organization’s marketing efforts, they found that their messaging didn’t quite align with the patients they were treating and hoping to target.
The four accrediting bodies in behavioral healthcare have different measures, however, there are some similarities when it comes to the site visit or survey portion of the process. Here are 15 tips from the experts.
Those who are working tirelessly to address the opioid crisis were disheartened by a recent report that describes how profitable drug distributors influenced a policy that reduced the DEA’s ability to stop diversion.